Characterization of Bacteroides fragilis from the vagina of a giant panda (Ailuropoda melanoleuca) with vaginitis Authors: Chanjuan Yue, Xiaoping Ma, Wanjing Yang, Yiyan Liu, Zhisong Yang, Rong Hou, Xia Yan, Mei Yang, Xiaoyan Su, Songrui Liu Published: 2024 ABSTRACT AbstractBackgroundBacteroides fragilis is a prevalent anaerobic bacterium typically resides in the human vagina. It is known to potentially induce infections under specific conditions. Interestingly, there have been no previous reports of B. fragilis being isolated from the vagina of giant pandas.Case presentationA novel strain of anaerobic bacteria was isolated from the vaginal tract of a giant panda exhibiting symptoms of vaginitis. This strain, designated as GPBF01, was identified as Bacteroides fragilis, a species commonly found in the vaginal microbiome of humans and other animals. After purifying of the single colony, a series of evaluations were conducted including morphological examination, physiological and biochemical identification, antibiotic resistance analysis, resistance genes detection, 16S rRNA sequence, and phylogenetic tree sequence analysis to investigate its biological characteristics. The findings indicated the presence of a predominant anaerobic bacterium, which was identified as B. fragilis and temporarily named GPBF01 with unique biological traits not previously.ConclusionsThis study is the first to report B. fragilis in the vaginal tract of giant pandas. The analysis of antibiotic resistance patterns among anaerobic bacteria, as conducted in this research, is critical for informing the selection of appropriate antimicrobial agents in the clinical treatment of vaginitis in this species. The findings of this report substantially enhance the scientific basis needed to understand the etiology and refine therapeutic approaches for vaginitis in giant pandas.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12917-024-04401-4.Keywords: Giant panda, Bacteroides fragilis, 16S Rrna, Physiological and biochemical reactions, Antibiotic resistance Background The giant panda (Ailuropoda melanoleuca), a rare and endemic species to China, is classified as Vulnerable (VU) by the International Union for Conservation of Nature (IUCN). Assessing the health of the reproductive system in giant pandas is crucial to advancing conservation efforts [1]. Bacteroides fragilis (B. fragilis), a representative species of the genus Bacteroides, is a Gram-negative, obligate anaerobic, non-spore-forming, and non-motile rod-shaped bacterium commonly found in the intestines, oral cavity, and reproductive tract of mammals [2]. However, to date, there have been no reports of Bacteroides fragilis isolated from the vaginal microbiota of giant pandas. This absence of documentation underscores a significant gap in the current understanding of the vaginal microbiome in this species. A comprehensive analysis of the biological characteristics of the bacterial isolate was conducted to elucidate its specific traits. Case presentation In September 2019, a female adult giant panda with a history of breeding, living at the Chengdu Research Base of Giant Panda Breeding, exhibited symptoms of vaginitis such as perineal rubbing, vulvar erythema and swelling, increased viscous discharge, diminished appetite, and signs of restlessness. The vaginal swabs collected from the giant panda were subjected to aerobic bacterial and fungal cultivation, as well as anaerobic bacterial culture. Escherichia coli was isolated in the aerobic bacterial cultivation, and no fungi were found. Then the samples were then inoculated into Brain–Heart Infusion (BHI) broth and incubated at 37℃ in an anaerobic incubator shaker for 18 h. Subsequently, the bacterial suspension was streaked onto Bile Esculin Azide agar (BBE) medium supplemented with hemin. The inoculated plates were then placed within a portable anaerobic chamber equipped with an anaerobic gas-generating packet, and incubated at 37℃ for an additional 24 h. Colonies of the isolated strain, measuring 1 to 3 mm in diameter, were round, slightly convex, translucent, and white with smooth surfaces. The medium beneath the colonies displayed black discoloration (Fig. 1). Following incubation, a single colony was subjected to Gram staining [3], involving fixation, crystal violet staining, iodine treatment, alcohol decolorization, and counterstaining with safranin according to the manufacturer's instruction. This was followed by microscopic examination using Olympus CX3 microscope (Japan). The bacterium was found to be Gram-negative; it stained light red color and exhibited typical rod-shaped bacterial cells with blunt ends and deep staining, along with an unstained, vacuole-like central region (Fig. 2). Isolates colony on BBE agar medium (24 h post incubation). The colonies of the isolated strain were round slightly convex, translucent, and white with smooth surfaces. And the medium beneath the colonies exhibited a black discoloration Gram staining of isolates colony (1000 ×). The gram stain of isolates GPBF01 was Gram-negative, and showed a typical rod-shaped pattern with blunt ends and intense staining. The arrow points to a distinct unstained area inside the bacterial cell The isolate was further analyzed using by PCR (Polymerase Chain Reaction). DNA from the 1.5 mL isolated strain solution after overnight cultured was extracted using a bacterial genomic DNA extraction kit (Tiangen®, Beijing, China) according to the manufacturer’s instructions. The 16S rRNA was amplified using a pair of universal primers (27F: 5'-AGAGTTTGATCCTGGCTCAG-3' and 1492R: 5'-TACGACTTAACCCCAATCGC-3'.). The PCR cycle was as follows: 94 ℃ for 5 min, followed by 35 cycles at 94 ℃ for 1 min, 54 ℃ for 1 min, 72 ℃ for 1 min. And with a final extension at 72 ℃ for 10 min. The PCR products were analyzed by electrophoresis, resulting in an amplified fragment about 1500 bp being obtained. To fragment of about 1500 bp identified by 16S rRNA PCR was sent for sequencing (Shenggong, Shanghai, China) to determine the species. The sequencing results were analyzed using BLAST® on the National Center for Biotechnology Information (NCBI) database (https://www.ncbi.nlm.nih.gov/). The sequence of 16S rRNA showed a nucleotide identity of 99.99% compared to that of the B. fragilis in GenBank (GenBank accession No. CP012706.1), confirming that the isolate was B. fragilis. We temporarily named the isolate GPBF01 for the convenience of experimental documentation. Phylogenetic analysis of the 16S rRNA sequence showed GPBF01 is positioned in a clade with high bootstrap support (100%) alongside three other B. fragilis strains (Fig. 3). This phylogenetic concordance, along with molecular identification through BLAST®, substantiates the classification of the isolated strain as B. fragilis. Phylogenetic tree generated on 16S rRNA gene of isolates GPBF01 and other sequence. Phylogenetic analysis was performed using Molecular Evolutionary Genetics Analysis version 7 (MEGA7.0) based on Maximum Likelihood model. Bootstrap values out of 1,000 repetitions were indicated above each branch. The scale bar represents 0.5-nucleotide change per nucleotide position Physiological characteristics and biochemical analysis were performed to further verify the isolate GPBF01. The standard strain of B. fragilis ATCC9394 was purchased from Beijing Annorun Biotechnology Co., Ltd. Both GPBF01 and ATCC9394 displayed positive catalase activity, negative results for gelatin liquefaction and motility tests and hemolysis test, and did not exhibit alpha or beta-hemolytic activity (Fig. 4). The results of biochemical test (Table 1) showed that both strains demonstrated consistent biochemical reactions across 61 assays, including glycogen and L-rhamnose. Meanwhile, the isolated strain GPBF01 exhibited a different metabolism of substances such as amygdalin, cellobiose, arbutin, dextrin, mannitol, gentiobiose, glucose-1-phosphate, lactulose, and inosine, in comparison to the B. fragilis standard strain ATCC9394. The growth curve analysis results showed that the isolate GPBF01 strain transitioned entered the logarithmic phase of growth at 8 h and remained there until the 12th hour before reaching the stationary phase at 16 h (Fig. 5A). The aerobic culturing test (Fig. 5B) showed that the isolate GPBF01 strain possesses a notable capacity for oxygen tolerance, reaching peak concentration by the 12th hour, reflecting an 8.5-fold increment over the initial bacterial count. The oxygen tolerance enabled the isolated strain to colonize in the vaginal environment. Hemolysis assays of isolate. A Case strain B. fragilis GPBF01 in blood plate, B Control strain B. fragilis ATCC9394 in blood plate Table 1Biochemical Identification Experiment Results of the strain GPBF01SubstanceATCC9394GPBF01SubstanceATCC9394GPBF01Water--D-Mannitol--N-Acetyl-D-Galactosamine + + D-Gluconose + + N-Acetyl-D-Glucosamine + + D-Pinitol--N-Acetyl-β-D-Mannosamine--D-Melibiose--Glucosaminic Acid--3-Methyl-D-Glucose + + Amygdalin + -α-Methyl-D-Galactoside--D-Arabitol--β-Methyl D-Glucose--Arbutin + -α-Methyl D-Glucoside--D-Cellobiose + -β-Methyl-D-Glucoside--α-Cyclodextrin- + 6-O-D-Glucopyranosyl-D-Fructofuranoside + + β-Cyclodextrin- + D-Heterose--Dextrin + -L-Rhamnose + + Adonitol + -Salicin--i-Inositol--D-Sorbitol--D-Fructose + + Stachyose--L-Fucose + + Turanose--D-Galactose + + D-Fucitol--D-Galacturonic Acid + + Pinitol + + Gentiobiose + -Acetic Acid--D-Gluconic Acid--Formic Acid--D-Aminoglucuronate--Methylsuccinic Acid--α-D-Glucose + + Glyoxylic Acid + + Glucose-1-Phosphate + -a-Hydroxybutyric Acid--Glucose-6-Phosphate + + β-Hydroxybutyric Acid--Glycerol--Itaconic Acid--D,L-α-Glycerophosphate--α-Ketobutyric Acid + + M-Fibrol--α-Ketoglutaric Acid + + α-D-Lactose--D,L-Lactic Acid--Lactose + -L-Lactic Acid--Maltose--D-Maltolactic Acid--Maltose Trisaccharide--D-Malic Acid--L-Malic Acid--L-Glutamate--Propionic Acid--Glutamyl-L-Glutamic Acid--Acetoacetic Acid + + Glutamyl-L-Amine--Methyl pyruvate--Glutamyl-L-Methionine--D-Glucuric Acid--Glutamyl-Proline--Succinimide Acid--L-Methionine--α-Succinic Acid + + L-Phenylalanine--Succinic Acid Methyl Ester + + L-Serine--Methyltartaric Acid--L-Threonine--L-Uracil Acid--L-Valine--Aminovaleric Amine--L-Valine + L-Aspartic Acid--L-Proline--2'-Deoxyadenosine + -L-Prolyl-L-Glutamic Acid--Inosine + -L-Prolyl-L-Histidine--Thymidine + + L-Prolyl-L-Serine--Uridine + + L-Asparagine--Thymidine-5'-Monophosphate--L-Glutamic Acid--Uridine-5'-Monophosphate-- + = Positive,- = Negative Biochemical Identification Experiment Results of the strain GPBF01 + = Positive,- = Negative Growth curve and Oxygen tolerance line graph of GPBF01. A Growth curve of GPBF01 in anaerobic environment in 48 h, GPBF01-1, GPBF01-2, GPBF01-3 shows that the experiment was repeated three times. B Oxygen tolerance line graph of GPBF01, concentration change of GPBF01 in aerobic environment for 100 h The chromosomal DNA of strain GPBF01 was utilize as the template. The Wafergen SmartChip Real-time PCR system was employed to analyze the antibiotic resistance genes present on the GPBF01 chromosome [4]. Each sample was tested in triplicate. After the initial activation of enzymes at 95 ℃ for 10 min, 30 cycles of the amplification procedure were conducted, which include denaturation at 95 ℃ for 30 s, and annealing at 60 ℃ for 30 s. Then, the results were analyzed using SmartChip qPCR software to exclude the wells exhibiting multiple melting peaks or amplification efficiencies outside the acceptable range of 90% to 110%. The calculation method was based on a previous study [4]. In brief, the relative copy number mapping calculated as follows: copy number (gene) / copy number (16S), indicating that both copy numbers pertain to the same sample. The copy number was determined using the formula: copy number = copy number = 10^(33—CT) / (10/3). If the offline data has a null CT value, then the CT value is assigned as 33, and the corresponding copy number value is set to 1. The result demonstrate that the isolated strain GPBF01 harbors three distinct resistance genes: cfxA, cepA, and copA. Following the guidelines of the "2012 Edition-Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria" [5], the microdilution broth method was used. A panel of 14 antibiotics, including 7 major categories, was selected: Cefotaxime sodium, ceftizoxime, meropenem, ampicillin/sulbactam, streptomycin, kanamycin, chloramphenicol, clarithromycin, tetracycline hydrochloride, polymyxin B, levofloxacin, moxifloxacin hydrochloride, trimethoprim, metronidazole. Results were interpreted according to Clinical and Laboratory Standards Institute (CLSI) criteria [6]. The results of the antibiotic resistance test showed that this strain is sensitive to meropenem, chloramphenicol, clarithromycin, tetracycline hydrochloride, levofloxacin, and metronidazole, but resistant to the remaining 8 antibiotics. These findings indicated that the strain is multidrug-resistance. Details of the antibiotics used and the results of the antibiotic resistance tests are provided in the supplementary material (Table S1 and Table S2). Discussion and conclusions Inflammation of the lower reproductive tract in giant pandas may be due to various pathogens, including a significant proportion of anaerobic bacteria. Typically, anaerobic bacteria are integral to the normal flora of the body and contribute to the stabilizing of the vaginal environment. However, they can become pathogenic under certain conditions. Vaginitis in giant pandas has predominantly been attributed to fungal infections [7], particularly candidiasis [8]. Despite this, there is a scarcity of research concerning anaerobic bacteria within the reproductive tract of giant pandas, with existing studies primarily focusing on the structure of the reproductive tract flora, diversity analysis, and metabolic pathways [9]. The present study represents the first isolation and identification of anaerobic bacteria from the vagina of giant pandas. Previous research used 16S rRNA gene sequencing to investigate the vaginal microbial diversity in giant pandas, which showed that Azomonas, Porphyromonas and Corynebacterium had the highest genus levels in non-estrous female giant panda, while Escherichia, Streptococcus, and Bacteroides showed highest genus levels in estrous female giant pandas [9]. Previous research has significantly advanced the understanding of vaginal anaerobic bacteria in humans. Bacteroides species constitute over one-third of common clinical anaerobic bacterial infections [10]. Specifically, B. fragilis is identified as the predominant strain within the Bacteroides genus, representing more than half of the cases [11]. It is recognized as the most prevalent opportunistic pathogen among clinical anaerobic bacterial infections [12]. The morphological description of the isolated strain, temporarily named GPBF01, is consistent with the typical characteristics of B. fragilis as outlined in the Bergey's Manual of Determinative Bacteriology [2]. Molecular characterization of the GPBF01 strain was achieved through PCR amplification of the 16S rRNA gene, followed by phylogenetic analysis. This approach confirmed the strain's classification as B. fragilis. The growth curve of strain GPBF01 illustrates a typical bacterial growth pattern, with a robust logarithmic phase and a gradual transition to the stationary phase. The strain exhibited a remarkable aerobic tolerance, which is a crucial adaption to its oxygen-exposed habitat. This finding aligns with the research conducted by Lee [13]. This feature is imperative for bacterial survival and may inform our understanding of microbiome resilience in aerobic environments. In pursuit of identifying conditioned pathogens, we routinely tested for bacterial and fungal pathogens, yet no predominant pathogenic species were identified. The preliminary experimental outcomes indicate that the isolated strain B. fragilis GPBF01 could potentially be associated with the vaginitis observed in the giant panda. The B. fragilis strain GPBF01 was resistance to seven categories of antibiotics, including aminoglycosides, glycopeptides, sulfonamides, β-lactams, and quinolones. EUCAST reported “expected resistant phenotypes” for anaerobes that are usually resistant to aztreonam, aminoglycosides, polymyxin B and nalidixic acid [14]. The CLSI reported that Bacteroides were resistance to aminoglycosides, penicillin and ampicillin. Aztreonam, and nalidixic acid was not involved in our study, and the expected results of aminoglycosides and polymyxin B are consistent with those in our study. Additionally, compared with the standard strain, the strain GPBF01 showed resistance to ampicillin-sulbactam, which may be related to the cfxA and cepA gene. A previous study showed that the cfxA and cepA gene was seen widely distributed among Bacteroides species [4] and were related to β-lactamase. Furthermore, this strain was also resistant to ceftriaxone sodium, cefazoxime, moxifloxacin hydrochloride, and trimethoprim indicating that it is a multidrug-resistant strain. Due to the incomplete testing of resistance genes, an explanation for this phenomenon cannot be provided at present. Therefore, it is necessary to investigate this bacterium more thoroughly in future studies. The results suggest that we should avoid the useing these drugs in clinical medicine. These findings provide a genetic basis for the observed resistance phenotype, emphasizing the critical role of genetic analysis in understanding the mechanisms underlying antibiotic resistance in clinical isolates. The identification of these genes is essential for guiding the development of tailored therapeutic approaches and miproving the effectiveness of antimicrobial stewardship programs. B. fragilis is known to harbor a repertoire of β-lactamases, including the endogenous cephalosporinase cepA, the cfxA β-lactamase, and the cfiA metallo-β-lactamase [15]. Importantly, the insertion sequence (IS) element upstream of the cfiA gene is recognized as a significant genetic determinant that confer resistance to carbapenems [15]. The discrepancy between the high frequency of phenotypic antibiotic resistance and the infrequent detection of the corresponding resistance genes may be attributed to various factors, such as the host's immune system response and the selective pressures from antimicrobial agents [16]. Furthermore, mutations in their promoter regions can affect the expression of resistance genes, leading to suppressed gene expression and loss of resistance. This is illustrated by mutations in RpoB that increase minimum inhibitory concentration for rifampicin [17]. Therefore, treatment regimens for infections caused by specific bacterial pathogens must be guided by the outcomes of antibiotic resistance test to ensure the judicious use of antimicrobial agents. This is the first report of B. fragilis colonizing the vaginal tract of giant panda and providing a comprehensive analysis of its phenotypic attributes, physiological and biochemical reactions, antibiotic resistance profile, and molecular sequencing. The GPBF01 strain shows resistance to a range of antibiotics including cefotaxime sodium, ceftizoxime, ampicillin/sulbactam and moxifloxacin hydrochloride, as well as aminoglycosides, lipopeptides, and sulfonamides. The genital tract microbiome of human and other mammals constitutes a complex ecosystem where anaerobic bacteria such as Bacteroides species coexist with aerobic counterparts, with B. fragilis being notably predominant [7, 9, 18, 19]. As a common anaerobic species it poses potential risk for infection under certain conditions. This study provides a scientific foundation for understanding the etiology of vaginitis in giant pandas and warrants further exploration into the pathogenic potential and characteristics of this strain to effectively guide treatment protocols. Supplementary Information Supplementary Material 1. Supplementary Material 2. Acknowledgements We sincerely thank the veterinary staff and keepers of the Chengdu Research Base of Giant Panda Breeding for their participation in the sample collection work, and James Edward Ayala for reviewing the manuscript. Authors’ contributions Y.L. and W.Y. collected the samples of Giant Panda; C.Y. and X.M. performed the experments; Z.Y., X.Y. and M.Y. analyzed the data; R.H., C.Y. and X.S. were responsible for major of the experimental operations; R.H. and S.L. provided the funding acquisition; Y.L., W.Y., S.L., R.H. and C.Y. wrote the paper; S.L. and R.H. conceived and designed the experiments. All authors reviewed the manuscript. Funding This research was supported by the 14th Five-Year National Key Research, Development Program (2023YFF1305402), Sichuan Province Forestry and Grassland Technology Innovation Team Special Fund (ky-20230620–02-19) and Chengdu Research Base of Giant Panda Breeding (2020CPB-B04). Data availability The authors confirm that the data supporting the findings of this study are availablewithin the article. Declarations Ethics approval and consent to participate The authors confirm that the ethical policies of the journal, as noted on the journal’s author guidelines page, have been adhered to. This study was conducted in strict accordance with the Animal Management Regulations of the People’s Republic of China. All animal experiments were approved by the Animal Welfare Committee of the Chengdu Research Base of Giant Panda Breeding (IACUC No. 2019006). Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1. Supplementary Material 2. Data Availability Statement The authors confirm that the data supporting the findings of this study are availablewithin the article.